<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Perm Medical Journal</journal-id><journal-title-group><journal-title xml:lang="en">Perm Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Пермский медицинский журнал (сетевое издание "Perm medical journal")</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0136-1449</issn><issn publication-format="electronic">2687-1408</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">112471</article-id><article-id pub-id-type="doi">10.17816/pmj39512-20</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original studies</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Comorbid diseases and conditions of patients with a novel coronavirus infection COVID-19, who died in infectious hospital</article-title><trans-title-group xml:lang="ru"><trans-title>Коморбидные заболевания и состояния у больных новой коронавирусной инфекцией COVID-19, умерших в инфекционном госпитале</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khokhlova</surname><given-names>Yu. A.</given-names></name><name xml:lang="ru"><surname>Хохлова</surname><given-names>Ю. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Medical Sciences, Associate Professor, Department of Faculty Therapy</p></bio><bio xml:lang="ru"><p>доцент кафедры факультетской терапии, кандидат медицинских наук</p></bio><email>kho.julia@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Markelova</surname><given-names>L. N.</given-names></name><name xml:lang="ru"><surname>Маркелова</surname><given-names>Л. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Deputy Chief Physician for Medical Work</p></bio><bio xml:lang="ru"><p>заместитель главного врача по лечебной работе</p></bio><email>kho.julia@list.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Titova</surname><given-names>N. E.</given-names></name><name xml:lang="ru"><surname>Титова</surname><given-names>Н. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Medical Sciences ,Associate Professor, Department of General Medical Practice, Polyclinic Therapy with Course of Geriatrics, Faculty of Additional Professional Education</p></bio><bio xml:lang="ru"><p>доцент кафедры общей врачебной практики, поликлинической терапии с курсом гериатрии факультета дополнительного профессионального образования, кандидат медицинских наук</p></bio><email>kho.julia@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Smolensk State Medical University</institution></aff><aff><institution xml:lang="ru">Смоленский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Clinical Hospital № 1</institution></aff><aff><institution xml:lang="ru">Клиническая больница № 1</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-11-10" publication-format="electronic"><day>10</day><month>11</month><year>2022</year></pub-date><volume>39</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>12</fpage><lpage>20</lpage><history><date date-type="received" iso-8601-date="2022-11-09"><day>09</day><month>11</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-11-09"><day>09</day><month>11</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Эко-Вектор</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://permmedjournal.ru/PMJ/article/view/112471">https://permmedjournal.ru/PMJ/article/view/112471</self-uri><abstract xml:lang="en"><p><bold>Objective.</bold> To analyze the comorbid diseases and conditions in patients with a novel coronavirus infection COVID-19, who died in the infectious hospital.</p> <p><bold>Materials and methods.</bold> Analysis of 1202 postmortem epicrises and protocols of pathologicoanatomic study of patients, who died in the infectious hospital of Smolensk on the basis of Clinical Hospital № 1 was carried out.</p> <p><bold>Results.</bold> There prevailed elderly and old patients – 81.5 %, most of them suffered from cardiovascular diseases (CVD), first of all ischemic heart disease – 92 % and arterial hypertension – 94.8 %. The most frequent risk factors/comorbid background of CVD were obesity (53.7 %), type 2 diabetes mellitus – 29.8 %. Practically all patients suffered from chronic heart failure, each third – 2b–3 stage, III–IV functional class (30.1 %). The basic comorbid diseases/conditions during hospitalization period were myocardial infarction (3.8 %), acute coronary syndrome (5.2 %), cerebral stroke (6.1 %), pulmonary embolism (4.3 %), atrial fibrillation paroxysm (8.7 %), myocarditis/pericarditis (3.8 %). In 43.1 % of patients, the comorbid pathology was on the foreground as a concurrent/concomitant/basic disease (as a basic diseases – in 12.9 % of patients).</p> <p><bold>Conclusions.</bold> Among the dead patients with COVID-19 there prevail elderly and old patients, burdened for comorbidity. Most of all, cardiovascular pathology, complicated by heart failure and associated with obesity and type 2 diabetes mellitus has an impact of the outcome of disease.</p> <p>The comorbid diseases/conditions during hospitalization are determined, as a rule, by vascular thromboses of various localizations. In every tenth patient, the comorbid pathology was the direct cause of death.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель.</bold> Провести анализ коморбидных заболеваний и состояний у умерших больных с новой коронавирусной инфекцией COVID-19, находившихся на лечении в инфекционном госпитале.</p> <p><bold>Материалы и методы.</bold> Проведен анализ 1202 посмертных эпикризов и протоколов патолого-анатомического исследования пациентов, умерших в инфекционном госпитале г. Смоленска на базе ОГБУЗ «Клиническая больница № 1».</p> <p><bold>Результаты.</bold> Преобладали пациенты пожилого и старческого возраста – 81,5 %. Большинство страдали сердечно-сосудистыми заболеваниями (ССЗ), в первую очередь ишемической болезнью сердца – 92 % и артериальной гипертонией – 94,8 %. Наиболее частые факторы риска/коморбидный фон ССЗ – ожирение (53,7 %), сахарный диабет 2-го типа – 29,8 %. Практически все пациенты страдали хронической сердечной недостаточностью, каждый третий – стадии 2б–3, III–IV функционального класса (30,1 %). Основные коморбидные заболевания/состояния за период госпитализации – инфаркт миокарда (3,8 %), острый коронарный синдром (5,2 %), мозговой инсульт (6,1 %), тромбоэмболия легочной артерии (4,3 %), пароксизм фибрилляции предсердий (8,7 %), миокардит/перикардит (3,8 %). У 43,1 % пациентов коморбидная патология выступала на передний план как конкурирующее/сочетанное/основное заболевание (как основное заболевание – у 12,9 % пациентов).</p> <p><bold>Выводы.</bold> Среди умерших больных COVID-19 преобладают лица пожилого и старческого возраста, отягощенные по коморбидности. В первую очередь на исход заболевания оказывает влияние сердечно-сосудистая патология, осложненная сердечной недостаточностью и ассоциированная с ожирением и сахарным диабетом 2-го типа. Коморбидные заболевания/состояния за период госпитализации, как правило, обусловлены сосудистыми тромбозами различных локализаций. У каждого десятого пациента коморбидная патология непосредственно привела к смерти.</p></trans-abstract><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>коморбидные заболевания</kwd><kwd>смерть</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>коморбидные заболевания</kwd><kwd>смерть</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Richardson S., Hirsch J.S., Narasimhan M., et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; 323 (20): 2052–2059.</mixed-citation><mixed-citation xml:lang="ru">Richardson S., Hirsch J.S., Narasimhan M. et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; 323 (20): 2052–2059.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Grinevich V.B., Gubonina I.V., Doshchitsin V.L., Kotovskaya Yu.V., Kravchuk Yu.A., Ped V.I., Sas E.I., Syrov A.V., Tarasov A.V., Tarzimanova A.I., Tkacheva O.N., Trukhan D.I. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention 2020; 19 (4): 135–172 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Гриневич В.Б., Губонина И.В., Дощицин В.Л., Котовская Ю.В., Кравчук Ю.А., Педь В.И., Сас Е.И., Сыров А.В., Тарасов А.В., Тарзиманова А.И., Ткачёва О.Н., Трухан Д.И. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика 2020; 19 (4): 135–172.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G. et al. International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19. Russian Journal of Cardiology 2021; 26 (4): 116 –131 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г. и др. Международный регистр «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARSCoV-2 (AКТИВ SARS-CoV-2)»: анализ предикторов неблагоприятных исходов острой стадии новой коронавирусной инфекции. Российский кардиологический журнал 2021; 26 (4): 116–131.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Guan W.-J., Liang W.-H., Zhao Y. et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J 2020, available at: https://doi.org/ 10.1183/ 13993003.00547-2020.</mixed-citation><mixed-citation xml:lang="ru">Guan W.-J., Liang W.-H., Zhao Y. et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J 2020, available at: https:// doi.org/10.1183/13993003.00547-2020.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62.</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Clift A.K., Coupland C.A.C., Keogh R.H. et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020, available at: https://doi: 10.1136/bmj.m3731.</mixed-citation><mixed-citation xml:lang="ru">Clift A.K., Coupland C.A.C., Keogh R.H. et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 2020, available at: https://doi: 10.1136/bmj.m3731.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Abate S.M., Checkol Y.A., Mantefardo B. Global prevalence and determinants of mortality among patients with COVID-19: A systematic review and meta-analysis. Ann Med Surg (Lond) 2021; 64, available at: https://doi: 10.1016/ j.amsu.2021.102204.</mixed-citation><mixed-citation xml:lang="ru">Abate S.M., Checkol Y.A., Mantefardo B. Global prevalence and determinants of mortality among patients with COVID-19: A systematic review and meta-analysis. Ann Med Surg (Lond). 2021; 64, available at: https://doi:10.1016/ j.amsu.2021.102204.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Likstanov M.I., Romasyuk A.V., Gatin V.R., Kazakova O.S., Oshlykova A.M., Mozes V.G. The role of cardiovascular comorbidity in the development of unfavorable outcomes of SARSCoV-2 in a level III hospital. Bulletin of Medical Science 2021; 2 (22): 31–37 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Ликстанов М.И., Ромасюк А.В., Гатин В.Р., Казакова О.С., Ошлыкова А.М., Мозес В.Г. Роль сердечно-сосудистой коморбидности в развитии неблагополучных исходов SARS-CoV-2 в стационаре III уровня. Бюллетень медицинской науки 2021; 2 (22): 31–37.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><mixed-citation>Tomasoni D., Inciardi R.M., Lombardi C.M. et al. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study. Eur J Heart Fail. 2020; 22 (12): 2238–2247.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Noor F.M., Islam M.M. Prevalence and Associated Risk Factors of Mortality Among COVID19 Patients: A Meta-Analysis. J Community Health. 2020; 45: 1270–1282.</mixed-citation></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Sattar N., McInnes I.B., McMurray J.J.V. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. Circulation 2020; 142: 4–6.</mixed-citation><mixed-citation xml:lang="ru">Sattar N., McInnes I.B., McMurray J.J.V. Obesity Is a Risk Factor for Severe COVID19 Infection: Multiple Potential Mechanisms. Circulation 2020; 142: 4–6.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Lippi G., Henry B.M. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020; 167, available at: https://doi: 10.1016/j. rmed.2020.105941.</mixed-citation></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Taneri P.E., Gómez-Ochoa S.A., Llanaj E. et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol. 2020; 35 (8): 763–73.</mixed-citation><mixed-citation xml:lang="ru">Taneri P.E., Gómez-Ochoa S.A., Llanaj E. et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur. J. Epidemiol. 2020; 35 (8): 763–73.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Boytsov S.A., Pogosova N.V., Paleev F.N., Ezhov M.V., Komarov A.L., Pevzner D.V. et al. Clinical Characteristics and Factors Associated with Poor Outcomes in Hospitalized Patients with Novel Coronavirus Infection COVID-19. Kardiologiia 2021; 61 (2): 4–14 (in Russian).</mixed-citation><mixed-citation xml:lang="ru">Бойцов С.А., Погосова Н В., Палеев Ф.Н., Ежов М.В., Комаров А.Л., Певзнер Д.В. и др. Клиническая картина и факторы, ассоциированные с неблагоприятными исходами у госпитализированных пациентов с новой коронавирусной инфекцией COVID-19. Кардиология 2021; 61 (2): 4–14.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Bilaloglu S., Aphinyanaphongs Y., Jones S. et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA 2020; 324 (8): 799-801.</mixed-citation><mixed-citation xml:lang="ru">Bilaloglu S., Aphinyanaphongs Y., Jones S. et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA 2020; 324 (8): 799–801.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Trejo-Gabriel-Galán J.M. Stroke as a complication and prognostic factor of COVID-19. Neurologia. 2020; 35 (5): 318–22.</mixed-citation><mixed-citation xml:lang="ru">Trejo-Gabriel-Galán J.M. Stroke as a complication and prognostic factor of COVID-19. Neurologia 2020; 35 (5): 318–22.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><mixed-citation>Kawakami R., Sakamoto A., Kawai K. et al. Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021; 77 (3): 314–25.</mixed-citation></ref></ref-list></back></article>
